AbbVie stock slipped slightly Friday, but the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi. The post AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real